Faslodex in McCune-Albright Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 8, 2009

Study Completion Date

July 20, 2023

Conditions
Puberty, PrecociousMcCune-Albright Syndrome
Interventions
DRUG

Fulvestrant

Participants will receive intramuscular injection of fulvestrant as stated in arm description.

Trial Locations (16)

10126

Research Site, Torino

10467

Research Site, The Bronx

19104

Research Site, Philadelphia

33000

Research Site, Bordeaux

33136

Research Site, Miami

35233

Research Site, Birmingham

40508

Research Site, Lexington

49082

Research Site, Osnabrück

69677

Research Site, Bron

70808

Research Site, Baton Rouge

75571

Research Site, Paris

84108

Research Site, Salt Lake City

91054

Research Site, Erlangen

117036

Research Site, Moscow

L12 2AP

Research Site, Liverpool

WC1N 3JH

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY